A Phase 1b, Multicenter, 2-Part, Open-Label Study Of DS-1062a In Combination With Durvalumab In Subjects With Advanced Or Metastatic Non-Small Cell Lung Cancer Without Actionable Genomic Alterations And Previously Treated With Platinum-Based Chemotherapy With Or Without Prior Immunotherapy Read more
A Phase 1 Trial Of MK-7684 As Monotherapy And In Combination With Pembrolizumab In Subjects With Advanced Solid Tumors Read more
Phase I/II, Two-Part, Multicenter First-In-Human Study Of DS-7300a In Subjects With Advanced Solid Malignant Tumors Read more
Phase 1b/2, Open-Label, Multicenter Study Of ERAS-007 In Combination With Other Anti-Cancer Therapies In Patients With Advanced Non-Small-Cell Lung Cancer (HERKULES-2) Read more
Long-Term, Non-Interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy Read more
FT500 As Monotherapy And In Combination With Immune Checkpoint Inhibitors In Subjects With Advanced Solid Tumors (Phase 1) Read more
A Phase I, Open-Label, Multicenter Study Of FT516 In Combination With Monoclonal Antibodies In Subjects With Advanced Solid Tumors Read more
Niraparib Plus Carboplatin In Patients With Homologous Recombination Deficient Advanced Solid Tumor Malignancies Read more
An Open Label, Multi-Center, Dose Escalation/Expansion, Phase 1 Study Of IMU-201 (PD1-Vaxx), A B-Cell Immunotherapy, In Adults With Non-Small Cell Lung Cancer Read more
